COVID-19 Human IgM IgG ELISA kit (Spike Protein)
Measurement method: Indirect ELISA
Measurement wavelength: 450 nm
Measurement sample: Serum
Species reactivity: Human
Storage temperature: Keep HRP-conjugated anti-human IgM/IgG antibody at or below -20 ° C.
Keep other reagents and immobilized plate at 2-8 ° C
Expiration date: This product is valid for 5 months after production.
Immobilized antige: SARS-CoV-2 spike protein (S1+S2 domain, mammalian expression system)
1. SARS-CoV-2 spike protein-immobilized plate
2. HRP-conjugated anti-human IgM antibody
3. HRP-conjugated anti-human IgG antibody
4. Washing buffer（10× PBST）
5. Non-fat milk (for blocking buffer)
6. Diluent buffer (10×)
7. R-1: Chromogenic substrate (TMB)
8. R-2: Stop reagent (1 mol/L hydrochloric acid)
9. Microplate seal
The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.
After the reaction, the sample is removed by washing.
React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human IgM / IgG antibodies.
Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.
Significance of measurement
This kit is a research ELISA kit to detect human IgM and IgG antibodies that recognize the spike protein of SARS-CoV-2, the causative virus of Covid-19.
Virus detection can be broadly divided into two approaches: one is to detect the virus itself, such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). In common infections, IgM is an antibody produced early in the infection and disappears with relief of symptoms. IgG begins to be produced later than IgM and continues to be produced for months after healing. This is known to reduce the symptoms of the next infection or to prevent the onset of the next infection
Mayara Lisboa Bastos et al.
Diagnostic Accuracy of Serological Tests for covid-19: Systematic Review and Meta-Analysis
BMJ. 2020 Jul. PubMed PMID: 32611558
AJ Jääskeläinen et al.
Performance of six SARS-CoV-2 immunoassays in comparison with microneutralization
J Clin Virol. 2020 Aug. PubMed PMID: 32563180
Baoqing Sun et al.
Kinetics of SARS-CoV-2 Specific IgM and IgG Responses in COVID-19 Patients
Emerg Microbes Infect. 2020 Dec. PubMed PMID: 32357808
Lancet. 2020 13-19 June. PubMed PMID: 32450106
Wan Ni Chia et al.
Serological Differentiation Between COVID-19 and SARS Infections
Emerg Microbes Infect. 2020 Jun 12. PubMed PMID: 32529906
Sci Immunol. 2020 Jun 11. PubMed PMID: 32527802
Nat Med. 2020 Jun 5. PubMed PMID: 32504052
Florian Krammer et al.
Serology assays to manage COVID-19
Science. 2020 Jun 5. PubMed PMID: 32414781
Nat Commun . 2020 Jun 1. PubMed PMID: 32483236
Curr Protoc Microbiol. 2020 Jun. PubMed PMID: 32302069
Huan Ma et al.
Serum IgA, IgM, and IgG responses in COVID-19
Cell Mol Immunol. 2020 May 28. PubMed PMID: 32467617
J Clin Microbiol. 2020 Jun. PubMed PMID: 32277023
Clin Microbiol Infect. 2020 May. PubMed PMID: 32473953
Nadin Younes et al.
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
Viruses. 2020 May 26. PubMed PMID: 32466458
J Clin Microbiol . 2020 May 26. PubMed PMID: 32229605
Ling Zhong et al.
Detection of serum IgM and IgG for COVID-19 diagnosis
Sci China Life Sci. 2020 May. PubMed PMID: 32270436
Cell. 2020 May 20. PubMed PMID: 32473127
Trevor R F Smith et al.
Immunogenicity of a DNA Vaccine Candidate for COVID-19
Nat Commun. 2020 May 20. PubMed PMID: 32433465
J Infect. 2020 May 15. PubMed PMID: 32417311
J Clin Virol. 2020 Jul (Published online 2020 May 13.) PubMed PMID: 32434708
Fatima Amanat et al.
A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans
Nat Med. 2020 May 12. PubMed PMID: 32511441
Jiajia Xie et al.
Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test
J Med Virol. 2020 May 7. PubMed PMID: 32330303
Rongqing Zhao et al.
Early Detection of SARS-CoV-2 Antibodies in COVID-19 Patients as a Serologic Marker of Infection
Clin Infect Dis. 2020 May. PubMed PMID: 32357209
Hongzhou Lu et al.
An Evolving Approach to the Laboratory Assessment of COVID-19
J Med Virol . 2020 Apr 29. PubMed PMID: 32347966
Quan-Xin Long et al.
Antibody Responses to SARS-CoV-2 in Patients With COVID-19
Nat Med. 2020 Apr 29. PubMed PMID: 32350462
Juanjuan Zhao et al.
Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019
Cin Infect Dis. 2020 Mar 28. PubMed PMID: 32221519
J Med Virol. 2020 Apr 28. PubMed PMID: 32343415
Chenguang Shen et al.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
JAMA. 2020 Apr 28. PubMed PMID: 32219428
Clin Chim Acta. 2020 Aug. PubMed PMID: 32343948
Nisreen M A Okba et al.
Emerg Infect Dis. 2020 Apr 8. PubMed PMID: 32267220
1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)
2.)Anu Haveri , “Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland,” January to February 2020 , Eurosurveillance. Volume 25, Issue 11, 19, Mar 2020.
3.)Wanbing Liu, “Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2”, J Clin Microbiol. 2020 Mar 30.
4.)Li Guo, “Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)”, Clin Infect Dis. 2020 Mar 21.
5.)Juanjuan Zhao, “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, Clin Infect Dis. 2020 Mar 21.